Radical prostatectomy reigns supreme

ONCOLOGY

Volumn 23, Issue 10, 2009, Pages

  Rayala, Heidi J ^a   Richie, Jerome P ^a   Cutler, Elliott C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; URINE INCONTINENCE;

EID: 72449171030     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. American Cancer Society: Detailed guide: Prostate cancer. Available at www.cancer.org. Accessed July 21, 2009.
2. Berger AP, Spranger R, Kofler K, et al: Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Prostate 57:93-98, 2003. (Pubitemid 37204489)
3. Bill-Axelson A, Holmberg L, Filen F, et al: Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100:1144-1154, 2008.
4. DAmico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998. (Pubitemid 28445094)
5. Penson DF, Rossignol M, Sartor AO, et al: Prostate cancer: Epidemiology and health-related quality of life. Urology 72:S3-S11, 2008.
6. Klein EA, Bianco FJ, Serio AM, et al: Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 179:2212-2217 (incl discussion), 2008.
7. Grossfeld GD, Chang JJ, Broering JM, et al: Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 165:851-856, 2001.
8. Freedland SJ, Partin AW, Epstein JI, et al: Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer 100:1646-1649, 2004. (Pubitemid 38456341)
9. Thompson IM, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. J Urol 181:956-962, 2009.
10. Cookson MS, Aus G, Burnett AL, et al: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540-545, 2007.
11. Roach M 3rd, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006. (Pubitemid 43914244)
12. Nielsen ME, Makarov DV, Humphreys E, et al: Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterionnadir + 2? Urology 72:389-395 (incl discussion), 2008.
13. Koppie TM, Grossfeld GD, Miller D, et al: Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol 164:81-88, 2000.
14. Klotz L: Active surveillance for favorable-risk prostate cancer: Who, how and why? Nat Clin Pract Oncol 4:692-698, 2007. (Pubitemid 350187004)
15. DAmico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95:281-286, 2002. (Pubitemid 34787593)
16. Crook J, Ludgate C, Malone S, et al: Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60:15-23, 2004. (Pubitemid 39165464)
17. DAmico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004. (Pubitemid 39079668)
18. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002. (Pubitemid 34786197)
19. Scolieri MJ, Altman A, Resnick MI: Neoadjuvant hormonal ablative therapy before radical prostatectomy: A review. Is it indicated? J Urol 164:1465-1472, 2000.
20. Potosky AL, Davis WW, Hoffman RM, et al: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst 96:1358-1367, 2004. (Pubitemid 39406169)
21. Trock BJ, Han M, Freedland SJ, et al: Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760-2769, 2008. (Pubitemid 351846851)
22. Van der Kwast TH, Bolla M, Van Poppel H, et al: Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25:4178-4186, 2007. (Pubitemid 47548556)
23. Ward JF, Sebo TJ, Blute ML, et al: Salvage surgery for radiorecurrent prostate cancer: Contemporary outcomes. J Urol 173:1156-1160, 2005.
24. Peeters ST, Heemsbergen WD, Koper PC, et al: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990-1996, 2006.
25. Pollack A, Zagars GK, Starkschall G, et al: Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1105, 2002. (Pubitemid 34787842)
26. Zietman AL, DeSilvio ML, Slater JD, et al: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294:1233-1239, 2005. (Pubitemid 41352111)
27. Kuban DA, Tucker SL, Dong L, et al: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74, 2008. (Pubitemid 350251041)
28. Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250-1261, 2008.
29. Keating NL, OMalley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456, 2006. (Pubitemid 46630983)
30. Miller DC, Sanda MG, Dunn RL, et al: Long-term outcomes among localized prostate cancer survivors: Health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23:2772-2780, 2005.
31. Speight JL, Elkin EP, Pasta DJ, et al: Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: Data from CaPSURE. Int J Radiat Oncol Biol Phys 60:1066-1075, 2004.
32. Wei JT, Dunn RL, Sandler HM, et al: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20:557-566, 2002. (Pubitemid 34072540)
33. Fransson P, Widmark A: Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: A comparison with age-matched controls. Cancer 85:678-688, 1999. (Pubitemid 29075289)
34. McDermott DW, Sanda MG: Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4. Nat Clin Pract Urol 6:124-125, 2009.
35. Menon M, Tewari A, Baize B, et al: Prospective comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy: The Vattikuti Urology Institute experience. Urology 60:864-868, 2002. (Pubitemid 35300356)
36. Hegarty NJ, Kaouk JH: Radical prostatectomy: A comparison of open, laparoscopic and robot-assisted laparoscopic techniques. Can J Urol 13(suppl 1):56-61, 2006.
37. Mouraviev V, Nosnik I, Sun L, et al: Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: A single-institution experience. Urology 69:311-314, 2007. (Pubitemid 46274941)
38. Hu JC, Wood D, Andriole G, et al: Perioperative quality of care indicators or retropubic, laparoscopic, and robotic prostatectomy: Results from a national, multi-center, prospective cohort. J Urol 175(suppl):371, 2006.
39. Cooperberg MR, Lubeck DP, Meng MV, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2149, 2004.